Abstract
For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem.
Copyright © 2011 Elsevier Inc. All rights reserved.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / administration & dosage
-
Bacteremia / drug therapy*
-
Bacteremia / microbiology
-
Carbapenems / administration & dosage*
-
Ertapenem
-
Escherichia coli / enzymology*
-
Escherichia coli / isolation & purification
-
Escherichia coli Infections / drug therapy*
-
Escherichia coli Infections / microbiology
-
Female
-
Humans
-
Imipenem / administration & dosage
-
Klebsiella Infections / drug therapy*
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae / enzymology*
-
Klebsiella pneumoniae / isolation & purification
-
Male
-
Meropenem
-
Middle Aged
-
Thienamycins / administration & dosage
-
Treatment Outcome
-
beta-Lactamases / biosynthesis*
-
beta-Lactams / administration & dosage
Substances
-
Anti-Bacterial Agents
-
Carbapenems
-
Thienamycins
-
beta-Lactams
-
Imipenem
-
beta-Lactamases
-
Meropenem
-
Ertapenem